Hyperbaric Prilocaine 2% vs Hyperbaric Bupivacaine 0.5% in Caesarean Section

NCT ID: NCT06680167

Last Updated: 2024-11-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

EARLY_PHASE1

Total Enrollment

142 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-10-09

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Comparison between effects of hyperbaric bupivacaine 0.5% vs Hyperbaric prilocaine 2% in spinal anesthesia of women undergoing elective caesarean section such as onset time of sensory and motor block, duration of sensory and motor block, effects of maternal hemodynamics and expected side effects .

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients will be randomly allocated into two groups:

1. Prilocaine Group (Group A):

* Patients will receive 60 mg of hyperbaric prilocaine 2% intrathecally.
* The anesthetic solution will be injected intrathecally using a 25 Gauge spinal needle, with the patient in a sitting position (midline or paramedian technique).
* The injection will be performed at the L3-L4 or L4-L5 interspace.
2. Bupivacaine Group (Group B):

* Patients will receive 12.5 mg of hyperbaric bupivacaine 0.5% intrathecally.
* The anesthetic solution will be injected intrathecally using a 25 Gauge spinal needle, with the patient in a sitting position (midline or paramedian technique) .
* The injection will be performed at the L3-L4 or L4-L5 interspace.

Procedure Details:

Prior to the procedure, patients will be preloaded with 500 ml of balanced crystalloid solution intravenously. Patients will be positioned in the sitting position for the spinal injection.

The chosen interspace (L3-L4 or L4-L5) will be identified, and the skin will be prepared with an antiseptic solution. A 25 Gauge spinal needle will be used for the intrathecal injection (midline or paramedian technique). After confirming free flow of cerebrospinal fluid, the prepared anesthetic solution will be injected over 10-15 seconds. Following the injection, patients will be placed supine with a slight left lateral tilt to avoid aortocaval compression. The sensory block level will be assessed using Pinprick sensation test, and the motor block will be evaluated using the modified Bromage scale. 5 Blood pressure and heart rate will be monitored every 5 mins until the end of the surgery. In case of hypotension (systolic BP \< 90 mmHg or diastolic BP \< 60 mmHg), intravenous boluses of 10 mg ephedrine will be administered until blood pressure stabilizes. In case of Bradycardia with Heart rate \<55 bpm atropine sulphate 0.01 mg/kg will be given intravenous. Pain Assessment will be done postoperatively via Visual analogue score (VAS) as following if score 3 or less no analgesia required if score 4-5, 1g paracetamol iv will be given if score 6-7, 30mg ketorolac iv will be given if score 7 or more, 2.5mg morphine sulphate iv will be given

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spinal Anesthesia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

SINGLE

Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients of group A will receive 60mg of hyperbaric prilocaine 2% for spinal anesthesia

Group Type ACTIVE_COMPARATOR

spinal anesthesia (hyperbaric Prilocaine 2%)

Intervention Type DRUG

60mg of Hyperbaric Prilocaine 2% will be injected intrathecally for women undergoing elective caesarean section

patients of group B will receive 12.5mg heavy bupivacaine for spinal anesthesia

Group Type ACTIVE_COMPARATOR

Spinal anesthesia (heavy bupivacaine 0.5%)

Intervention Type DRUG

12.5mg of Heavy bupivacaine 0.5% will be injected intrathecally for women undergoing elective caesarean section

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Spinal anesthesia (heavy bupivacaine 0.5%)

12.5mg of Heavy bupivacaine 0.5% will be injected intrathecally for women undergoing elective caesarean section

Intervention Type DRUG

spinal anesthesia (hyperbaric Prilocaine 2%)

60mg of Hyperbaric Prilocaine 2% will be injected intrathecally for women undergoing elective caesarean section

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Women aged 18-45 years.
2. Patients with uncomplicated pregnancies.
3. American society of anesthesiologist (ASA) physical status I or II.
4. Height between 155 cm and 175 cm.
5. Written informed consent provided. -

Exclusion Criteria

1. Patients with known allergies to local anesthetics.
2. Contraindications to intrathecal anesthesia (e.g., infection at the injection site and coagulopathy).
3. Severe preeclampsia or eclampsia.
4. Presence of significant comorbidities (e.g., uncontrolled diabetes, hypertension, renal or hepatic dysfunction).
5. History of spinal surgery or significant spinal deformity.
6. Patients who refuse to participate in the study -
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sohag University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mostafa Mohamed Abdelgaber

A Comparative Study between Hyperbaric Prilocaine 2% versus Hyperbaric Bupivacaine 0.5% For Intrathecal Anesthesia in Caesarean Section

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sohag University Hospitals

Sohag, Sohag Governorate, Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Soh-Med-15-10---6MS

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.